DaVita Stock Price and Value Analysis

DaVita (NYSE:DVA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold DaVita to reach your target.

Target type

DVA Free Cash Flow Trend

Free Cash Flow trendline for DVA
Free Cash Flow trendline for DaVita
CSV

Based on historical returns, we believe that DaVita can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is very stable.
  • This stock is available at a great discount!
  • This company is making money at a decent rate.
  • This company has stable growth.
None.
  • This company pays no dividend.

Inside the DVA Numbers

DVA Price
(DaVita stock price per share)
$161.03
[?] DVA Fair Price
(based on intrinsic value)
$378.04
[?] DVA Safety Price (based on a variable margin of safety) $302.43
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 39% lower than other Healthcare stocks
[?] PE Ratio versus Industry 16% higher than other Medical Care Facilities stocks
[?] Cash Yield 14.71%
[?] Free Cash Flow Jitter 22%

Insider Activity Summary

In the six months to 2026-11-22, no insider bought shares, and 1 insider sold in 1 trade, about $36.5 million.

The six months before that had 0 buys and 2 sales.

Recent Insider Activity

Open-market buys and sells reported by DaVita's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-07-31 BERKSHIRE HATHAWAY INC Sell 182,980 $199.55
2026-05-01 BERKSHIRE HATHAWAY INC Sell 1,220,376 $149.84
2026-01-29 BERKSHIRE HATHAWAY INC Sell 1,658,480 $120.56
2025-10-27 BERKSHIRE HATHAWAY INC Sell 401,514 $135.36
2025-07-31 BERKSHIRE HATHAWAY INC Sell 1,635,962 $140.61
2025-05-27 BERKSHIRE HATHAWAY INC Sell 19,330 $138.59
2025-05-27 BERKSHIRE HATHAWAY INC Sell 11,978 $140.18
2025-05-27 BERKSHIRE HATHAWAY INC Sell 71,966 $139.56
2025-05-23 BERKSHIRE HATHAWAY INC Sell 800 $138.60
2025-05-23 BERKSHIRE HATHAWAY INC Sell 36,094 $138.19

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,141,769 shares shorted. With 33,422,544 shares available for purchase and an average trading volume over the past 10 trading days of 770,390, it would take at least 6.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 927066 309
2008 927066 319
2009 927066 378
2010 927066 555
2011 927066 872
2012 927066 738
2013 927066 1,350
2014 927066 963
2015 927066 974
2016 927066 1,303
2017 927066 1,173
2018 927066 957
2019 927066 1,233
2020 927066 1,147
2021 927066 1,136
2022 927066 830
2023 927066 1,408
2024 927066 1,413
2025 927066 1,298

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $28,943 million against net income of $11,426 million, or 2.53 times.

In 2025, operating cash flow was 2.53 times net income, compared with 1.58 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $576 million, 30.5% of operating cash flow of $1,887 million, which leaves an estimated $1,311 million after capex. Across the 19 years with reported capex, it averaged 38.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 382 581 272 1.52
2008 374 614 318 1.64
2009 423 667 275 1.58
2010 406 840 274 2.07
2011 478 1,180 400 2.47
2012 536 1,101 550 2.05
2013 633 1,773 618 2.80
2014 723 1,459 641 2.02
2015 270 1,557 708 5.77
2016 880 1,972 829 2.24
2017 664 1,913 905 2.88
2018 159 1,772 987 11.11
2019 811 2,072 767 2.56
2020 774 1,979 675 2.56
2021 978 1,931 641 1.97
2022 560 1,565 603 2.79
2023 692 2,059 568 2.98
2024 936 2,022 555 2.16
2025 747 1,887 576 2.53

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $11,898 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $12,212 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $1,308 million, 100.8% of estimated free cash flow of $1,298 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 1,303 n/a 1,098 1,098 84.3%
2017 1,173 n/a 803 803 68.5%
2018 957 n/a 1,162 1,162 121.3%
2019 1,233 n/a 2,384 2,384 193.3%
2020 1,147 n/a 1,458 1,458 127.2%
2021 1,136 n/a 1,539 1,539 135.5%
2022 830 n/a 802 802 96.7%
2023 1,408 n/a 272 272 19.3%
2024 1,413 n/a 1,386 1,386 98.1%
2025 1,298 n/a 1,308 1,308 100.8%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $10,707 million in 2016 and $13,643 million in 2025, a compound annual growth rate of 2.7% over 9 years.

Revenue rose 6.5% from 2024 to 2025.

Our estimated free cash flow was $1,298 million in 2025, 9.5% of revenue. In 2016 the estimated margin was 12.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 10,707 1,303 12.2%
2017 10,877 1,173 10.8%
2018 11,405 957 8.4%
2019 11,388 1,233 10.8%
2020 11,551 1,147 9.9%
2021 11,619 1,136 9.8%
2022 11,610 830 7.1%
2023 12,140 1,408 11.6%
2024 12,816 1,413 11.0%
2025 13,643 1,298 9.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $676 million against total liabilities of $16,322 million, or 4.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 93.4% of total assets in 2025, compared with 74.9% in 2008, an increase of 18.4 percentage points.

Stockholders equity was negative in 2025, at -$374 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 9.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 7,286 411 5,459 1,827
2009 7,558 539 5,364 2,194
2010 8,114 860 6,077 2,037
2011 8,904 394 6,636 2,268
2012 16,015 534 12,098 3,917
2013 17,099 946 11,796 4,606
2014 17,617 737 11,427 5,360
2015 18,515 1,245 12,567 5,084
2016 18,756 675 12,933 4,850
2017 18,975 508 13,077 4,886
2018 19,110 323 14,077 3,908
2019 17,311 1,102 13,812 2,319
2020 16,989 325 14,092 1,567
2021 17,121 462 14,751 936
2022 16,928 244 14,703 876
2023 16,894 380 14,150 1,244
2024 17,285 795 15,194 396
2025 17,480 676 16,322 -374

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $161.03, our model's value equals that price if free cash flow grows an average of -6.2 percent a year over the 10 projection years. Our model assumes 5.1 percent a year for this stock, so the price implies growth of -6.2 percent, which is below the 5.1 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,490 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $128.82 -9.2%
Current price $161.03 -6.2%
20 percent above the current price $193.24 -3.8%
Our model (stored fair price) $378.04 5.1%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for DaVita under its current filer shows positive free cash flow.

DaVita's average free cash flow rose sharply, from $335 million in its earliest three years to $1,373 million in its latest three.

Free cash flow is fairly steady from year to year, with a variability measure of 22%.

At $161.03, DaVita trades below our safe value estimate of $302.43 and our fair value estimate of $378.04.

We do not have a dividend yield for DaVita.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 39% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 16% above the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to DaVita, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
DaVita (DVA) 10,129 12.2 - 14.7% 57% below
Universal Health Services (UHS) 10,345 7.5 0.5% 13.7% 71% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above
Surgery Partners (SGRY) 3,505 - - - 105% above
Progyny (PGNY) 2,630 32.8 - - 409% above
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below
U.S. Physical Therapy (USPH) 1,432 - 1.9% 3.0% 1% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 927066.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: DVA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in DVA

Does DaVita have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: DVA

This example shows how we apply the Trendshare checklist to DVA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 161.03
    • Market cap: $10B
    • EPS: 13.21
  2. Step 2 — Valuation checks

    • P/E: 12.19
    • FCF yield: 14.7%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.